Summit Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 24, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 24, 2025
SMMT$17.83-0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
| Year Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Revenue | $— | $— | $705 |
| Operating expenses: | |||
| Research and development | 150,777 | 59,471 | 51,999 |
| Acquired in-process research and development | 15,007 | 520,915 | — |
| General and administrative | 60,527 | 30,265 | 26,743 |
| Impairment of intangible assets | — | — | 8,468 |
| Total operating expenses | 226,311 | 610,651 | 87,210 |
| Other operating income, net | 313 | 1,001 | 14,416 |
| Operating loss | (225,998) | (609,650) | (72,089) |
| Other income (expense), net | 13,369 | 11,183 | (2,292) |
| Interest expense | (8,686) | (16,461) | (4,401) |
| Net loss | $(221,315) | $(614,928) | $(78,782) |
| Net loss per share: | |||
| Basic and diluted | $(0.31) | $(0.99) | $(0.41) |
| Weighted average common shares outstanding: | |||
| Basic and diluted | 718,541,896 | 619,646,180 | 193,336,063 |
| Other comprehensive income (loss): | |||
| Foreign currency translation adjustments | 60 | (172) | 304 |
| Reclassification of unrealized loss on short-term investments to other expense, net | 3 | — | — |
| Reclassification of cumulative currency translation gain to other expense, net | — | (419) | — |
| Unrealized gain on short-term investments | 100 | 36 | — |
| Comprehensive loss | $(221,152) | $(615,483) | $(78,478) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.